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Abstract
Background: Intravitreal injections (IVI) of anti-vascular endothelial growth factor (anti-VEGF) now improve or
stabilize visual acuity in a number of previously untreatable eye diseases, of which the main are age-related macular
degeneration, retinal vein occlusion and diabetic macular edema. Most patients require multiple injections over
lengthy periods of time and the prevalence of treatable conditions is increasing. Anti-VEGF IVI normally
administered by physicians, therefore represent a considerable workload on ophthalmologic clinics and will
continue to do so in the near future. Nurse-administered IVI may relieve this workload, but the safety, cost and
patient satisfaction of such an extended role for nurses in ophthalmologic clinics has not earlier been investigated.
To investigate these outcomes following independent anti-VEGF IVI by trained nurses, a noninferiority randomized
controlled trial is being conducted.
Methods/Design: Patients eligible for anti-VEGF treatment, minimum 304, are recruited and randomized to IVI
administration by either trained nurses or physicians. The primary outcome is safety, measured by difference in
mean change in visual acuity between the two groups during an observation period of 12 months. Secondary
outcomes are incidence of ocular adverse events, cost per patient and patient satisfaction.
Discussion: This study protocol describes the design of the first randomized controlled trial of nurse-administered
IVI of anti-VEGF. The study is designed to examine safety, cost and patient satisfaction during 12 months follow-up.
Trial registration: ClinicalTrials.gov NCT02359149. Registered February 4, 2015.
Keywords: Anti-VEGF, Intravitreal injection, Nurse, Randomized controlled trial, Age-related macular degeneration,
Retinal vein occlusion, Diabetic macular edema
Background
Intravitreal injections (IVI) of anti-vascular endothelial
growth factor (anti-VEGF) improve or stabilize visual
acuity in a number of previously untreatable eye dis-
eases, of which the main are age-related macular degen-
eration (AMD), retinal vein occlusion (RVO) and
diabetic macular edema (DME) [1–3]. Due to its potent
antiangiogenic effects, the number of IVI of anti-VEGF
has risen considerably since the treatment was first in-
troduced a decade ago [4, 5]. Elderly people with AMD
make up the largest group of patients receiving IVI and
the prevalence of the disease increases with age. In the
UK 3.5 % of the population of 75 years or older were
visually impaired due to AMD [6]. In 2010, more than
two million people were blind and six million people
were visually impaired due to macular diseases globally
[7]. Improved diagnostics as well as increased prevalence
of treatable conditions will probably cause a continued
rise of IVI in the future. IVI are normally administered
by physicians in ophthalmologic out-patient clinics and
are given with intervals of 4–16 weeks either as monthly
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injections, injections when needed (pro re nata) or injec-
tions with gradually extended intervals (treat and extend)
[8, 9]. Irrespective of the treatment strategy chosen, most
patients require sequential injections during several years
for their condition to stabilize. Hence, IVI of anti-VEGF
represent a considerable workload on physicians in oph-
thalmologic clinics and is expected to continue to do so.
This is a real challenge today and in the future, since the
population over age 60 are growing more than twice as
fast as the number of ophthalmologists [10].
Extended roles for nurses are increasingly imple-
mented in several medical fields, and in ophthalmology
nurse-administered IVI of anti-VEGF may replace
physician-administered IVI. Data on nurse-administered
IVI is limited so far, but there are indications that it may
be safe and acceptable to patients. An observational
study from the UK reported a complication rate compar-
able to studies in which IVI were administered by physi-
cians [11] and other studies have reported acceptable
patient satisfaction following nurse-administered IVI
[12–14]. However, these outcomes have to the best of
our knowledge not earlier been investigated in random-
ized controlled trials (RCT) and an economic evaluation
of a nurse-administered IVI clinic has not earlier been
reported. To this end, the present protocol describes a
noninferiority RCT with the objective to investigate
safety, cost and patient satisfaction following nurse-
administered IVI during 12-months follow-up.
Methods
Study design
The study is a prospective, randomized noninferiority trial
with two treatment arms; IVI performed by nurses and
IVI performed by physicians. Treatment by physicians is
considered the reference group and standard care to
which treatment performed by nurses will be compared.
The flow chart of the study is presented in Fig. 1.
Objectives
The primary objective is to evaluate the safety of nurse-
administered IVI of anti-VEGF compared with physician-
administered IVI.
The secondary objectives are:
 to evaluate cost of nurse-administered IVI of anti-
VEGF compared with standard care
 to evaluate patient satisfaction of nurse-administered
IVI of anti-VEGF compared with standard care
For the primary objective the evaluation will be per-
formed using a noninferiority test, to test whether the
nurses are treating the patients equally safe or better
than the reference group, i.e physicians. More specific-
ally, the null (H0) and alternative (HA) hypotheses are:
H0 : μNURSES– μPHYSICIANS≤−δL andHA
: μNURSES– μPHYSICIANS > − δL;
where μ i is the mean change in visual acuity from first
visit (baseline) to last visit 12 months later in group i,
and δL is “the noninferiority margin”, which is the max-
imum clinically acceptable difference in change, for
treatment by nurses to be considered noninferior to the
reference treatment, δL >0
Setting
The trial is performed in the IVI clinic of the Depart-
ment of Ophthalmology, St. Olavs Hospital, Trondheim
University Hospital in Norway during 01.03.15-31.12.16.
The IVI clinic, organized as an independent out-patient
clinic, performs ~ 3000 IVI annually and serves a popu-
lation of ~ 300.000 individuals in the Central Norway
Health Region.
Patients are remitted to the IVI clinic by ophthalmolo-
gists working at 10 different eye centers in the region and
from ophthalmologists at the Department of Ophthalmol-
ogy, responsible for the diagnostic and therapeutic deci-
sions. At the IVI clinic a secretary administers patient
appointments, receive user charges and answer phone
calls. Preparing the patients for IVI is performed by a
nurse (Additional file 1). In standard care, a physician is
responsible for performing the IVI according to the list of
patients, approximately 22 IVI daily (Additional file 2). A
senior consultant is available at the clinic in case medical
questions need to be discussed.
Intervention
The intervention in the present study consists of re-
placing the physician administering the IVI, by a nurse
(Additional file 2). Administration of IVI includes several
skills and responsibility: assessment of whether there are
any contraindications for treatment, performing the ster-
ile IVI procedure, informing the patient, planning the
next session and documentation in patient records. The
preparation for IVI by a nurse (Additional file 1) and the
possibility to seek medical advice from a senior consult-
ant remains equal to standard care.
Training program
A training program for administration of IVI for nurses
was developed and implemented at the Department of
Ophthalmology during the year prior to the start of the
RCT. Six nurses took part in the training program which
aimed at enabling nurses to perform IVI independently,
as safe and within equal time frame as the physicians.
The program included two interactive courses regard-
ing eye infections and documentation in patient records.
Furthermore, it included a wetlab with individual train-
ing of a safe injection technique on porcine eyes; placing
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the injection 3.5 mm posterior to the limbus in any
quadrant between the horizontal and vertical muscles.
This was followed by graded exposure of the procedure
in the injection room and finally performing IVI indi-
vidually on patients under the supervision of a physician.
The training program was divided into steps with in-
creasing difficulty and the participating nurses decided
themselves when they were ready to move to the next
step. The nurses had to perform 100 independent IVI
before final certification. The final achieved competence
was evaluated by an unbiased senior consultant via ob-
servation of the nurse performing three independent
IVI. If these were performed in a satisfactory manner,
the nurse was certified to administer IVI individually.
Trial recruitment
All patients with AMD, RVO or DME that are eligible for
anti-VEGF IVI and able to give an informed consent are
invited to participate. Both newly referred patients during
01.03.15–01.01.16 as well as patients that are already re-
ceiving anti-VEGF IVI fulfil the inclusion criteria.
Patients with ocular pathology eligible for anti-VEGF IVI
other than the abovementioned conditions and inability to
Fig. 1 Flowchart. Overview of the enrollment and follow-up of study participants
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provide an informed consent do not fulfil the inclusion cri-
teria and are excluded.
Information about the study will be given either face-
to-face in the department or via a phone call and will
also be handed out in writing. The patients will receive
trial information at least 24 h before being asked to give
an informed consent. If the patient agrees to enter the
trial, written informed consent will be obtained. Consent
forms will be stored in a locked safe to which only study
management has access. Patients who do not consent to
the trial will be treated according to standard care.
Randomization and blinding
Patients are randomly assigned to receive treatment by
nurse or physician in a 1:1 ratio, using a web-based algo-
rithm. The randomization is stratified by diagnosis
(AMD, RVO and DME) and by number of treatments
(first treatment vs treated before). The reason for choice
of stratification is that there is an expected difference in
change in mean visual acuity during the observation
period in these groups. Only one eye per patient is in-
cluded in the study. If both eyes are eligible, the eye with
the better visual acuity is included.
The study is single-blinded, i.e. patients are blinded to
intervention group. Patients are not told to which group
they have been randomized, and both nurses and physi-
cians will wear white hospital clothes but no nametags
telling their profession during the procedure. Further-
more, when the patient enters the injection room the
personnel will present themselves by first name only.
Outcomes
Primary outcome is the difference in mean change in
visual acuity between the two groups during the study
period of 12 months (measure 1).
Secondary outcomes are:
 incidence of ocular adverse events needing
treatment (measure 2)
 cost per patient (measure 3)
 mean patient satisfaction score (measure 4)
Measures
1. Visual acuity is measured with the Early Treatment
Diabetic Retinopathy Study (ETDRS) chart using a
standardized testing protocol at a starting test
distance of 2 m [4, 5]. The visual acuity is measured
as number of letters read at the ETDRS chart. Each
line of the chart has five letters of same size in each
row. The letters of the following rows gradually
become smaller, with a distance of 0,1 logMAR. This
interval scale is considered a continuous variable,
and the number of letters read is counted [15]. The
mean number of letters scored is considered a
precise measure for evaluating whether the
intervention shifts the visual acuity compared to
standard care.
The test is carried out under uniform conditions by a
physician, orthoptist or an optician. Before testing, the
refraction is corrected following a standard protocol
[15], i.e. the vision tested being the best corrected visual
acuity.
2. Ocular adverse events. Number of ocular adverse
events in the population receiving IVI at the
Department of Ophthalmology is recorded during
the whole study period, from the first study visit to
the last follow-up visit of the study. The ocular ad-
verse events will be noted in patient record and on a
dedicated study form. Only ocular adverse events
needing treatment are being recorded; retinal de-
tachment, retinal tears, endophthalmitis, uveitis, lens
damage and intraocular hemorrhages.
3. Cost per patient. Cost data will be collected in order
to take a hospital perspective, a health care
perspective and a societal perspective.
Intervention costs
The calculation of out-patient clinic costs will be based
on time spent by different personnel categories. Time
spent will be recorded according to the three main
phases of the treatment procedure: Pre-examination, the
IVI-procedure and the post IVI-procedure:
a) Pre-examination services performed by secretaries
and nurses
b) IVI-procedure performed by nurse (intervention) or
physician (standard care) and time spent by senior
consultant on on-call assistance to the nurse or
physician respectively.
c) Post-IVI services performed by secretaries.
Number of hours spent will be multiplied by personnel
group specific salary levels and adjusted with over-head
costs. Data will be recorded on a daily basis using prede-
fined registration forms (Additional file 3). Aggregate
costs per patient will be calculated.
Extra educational costs on training nurses will be cal-
culated based on the training program.
Other hospital costs
Utilization of hospital services outside the out-patient
clinic will be assessed by examining data from the hos-
pital administrative patient register. Costs will be calcu-
lated by combining volume of in-patient and out-patient
services and their corresponding unit costs.
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Health care costs outside hospital
Utilization of ophthalmologist services and general prac-
titioner services will be collected using a patient ques-
tionnaire (Additional file 4). Costs will be calculated by
combining volume of services and corresponding unit
costs.
Patient costs
Travel costs will be calculated based on information on
travel time and bringing a companion.
4. Patient satisfaction. Previously validated patient
satisfaction instruments were found too
comprehensive and not suitable to assess the IVI
treatment in the injection room setting. A short and
simple study-specific patient satisfaction question-
naire was therefore developed in accordance with
guidelines for measuring the quality of health ser-
vices [16]. The questionnaire was validated for reli-
ability and feasibility in a pilot study of 10 patients.
After this first pilot test, some modifications were
made to the questionnaire before a second pilot test
was carried out and validated. We found the best al-
ternative for the patients with blurred vision follow-
ing treatment to be a five-point grading scale and
only a few questions read out load. Only two aspects
of the treatment is tested; the general impression of
the treatment and the confidence during the treat-
ment in the injection room (Additional file 5). If the
patient is not giving the maximum score of satisfac-
tion, an open-ended question will be asked for rec-
ommendations of how to improve the comfort and
well-being during the visit. At the last visit, the pa-
tients additionally will be asked if they think they are
treated by a nurse or by a physician.
Data collection
At the first visit, background information for the eco-
nomic evaluations is collected (Additional file 4). A
physician, orthoptist or optician is asking these ques-
tions before refractioning the study eye and measuring
the best corrected visual acuity. The study participant
then goes to the injection room. After the IVI, the par-
ticipant is asked to answer the patient satisfaction ques-
tionnaire by a secretary (Additional file 5). Each study
participant has an individual study booklet marked with
study number and patient initials. The booklet follows
the patient during the visit in the department and is
otherwise kept in a locked room.
In the following visits the study participant will be
asked follow-up questions regarding use of health care
service (Additional file 4). The questions are asked by
the nurse or physician performing the IVI.
The last visit of the 12 month period is performed
similar to the baseline registration (Additional file 4).
The time window for the final test is 12 ± 2 months.
The nurse or physician performing the IVI, will fill in
a daily report including the number of patients and eyes
treated and number of questions asked a senior consult-
ant (Additional file 3).
Researchers will continually examine the study forms
in the booklets for missing data. Missing data will be
sought collected via phone calls.
Statistical methods
The primary objective will be analyzed using a t-test for
non-inferiority, comparing mean change in visual acuity
from baseline to 12 months between nurses and physi-
cians. A linear regression model for the change in visual
acuity will be used to compare the treatments after
adjusting for diagnosis, used as a stratification variable.
Adjusting for the other stratification variable, first or fol-
low up treatment, can be done similarly, but will depend
on a sufficient number of included patients in each of
the two groups. The data will be analyzed and presented
according to the CONSORT guidelines for reporting
noninferiority trials [17].
Costs will be examined by analyzing differences be-
tween nurses and physicians in total cost per patient,
health service cost per patient and hospital cost per pa-
tient. Imputation will be used on missing data. Sensitiv-
ity analyses will be performed to assess parameter
uncertainty.
Sample size
The sample size is calculated for the noninferiority study
comparing change in visual acuity for patients treated by
nurses to those treated by physicians.
Sample size considerations
In contrast to earlier studies comparing the effect of two
different anti-VEGF drugs or the effect of different anti-
VEGF treatment strategies, we want to test the effect of
two different professions performing the treatment. His-
torical data from large randomized clinical AMD trials
found the mean change in visual acuity during the first
year of treatment to be 6–7 letters (1,2–1,4 lines) [18].
The CATT study was as the present study designed as a
noninferiority study. As the noninferiority margin (δL)
should be less than the observed change in visual acuity,
five letters (one line on the visual acuity chart) was
chosen as the acceptable difference for the tested treat-
ment to be considered noninferior to the reference treat-
ment. However, in a study of the safety of nurse-
administered IVI, a noninferiority margin of five letters
may be considered too wide.
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First the study population in the present study is not
as homogenous as the before mentioned study since it
includes both patients with AMD, RVO and DME.
There is an anticipated difference in treatment response
in these three conditions. Second, the majority of study
participants will already have received several IVI before
inclusion in the study and in these patients we do not
expect major changes in visual acuity during the study
period. Third, we should consider the ethical aspect of
having a wide noninferiority margin; if it is right to sacri-
fice visual acuity to gain the possible benefit of cost sav-
ings by nurses treating the patients. Taking these aspects
into consideration, we find that the noninferiority mar-
gin should not exceed three letters. In other words, the
present study will test whether IVI administered by
nurses is not less effective than treatment by physicians,
by more than three letters.
We assume that the standard deviation (SD) of the
distribution of changes, σ, will be 10 letters. This is again
less than in the studies forming the basis for IVI of anti-
VEGF, finding a SD of 15 letters reasonable the first
year. The second year, however, the standard deviation,
dropped to 11 letters and in our study we do assume 10
letters would be reasonable [8].
The anticipated true difference between the treatment
groups is 0. That is, the effect of the treatment is ex-
pected to be equal in the two groups.
Sample size and power calculation
The sample size is calculated by using the abovemen-
tioned assumptions and the sample size formula for
comparing two means in a noninferiority trial (SPSS
Sample Power 3).
Choosing a noninferiority margin δL =3, standard devi-
ation SD = 10 and a significance level of 0.05, 140 partic-
ipants is required in each group to have a power of 80 %
to reject the null hypothesis, H0 ≤ - δL and conclude that
nurses are treating the patients equally safe as or better
than physicians, if the null hypothesis is true.
We anticipate the percentage of patients completing
the final visit at 12 months to be 92 % as a dropout of
8 %, including patient death and illness, is not uncom-
mon in similar trials. This means that to make sure that
140 participants complete a 12-month observation
period; at least 152 patients should be included in each
of the study arms.
Discussion
The primary objective of the study is to evaluate safety
of nurse-administered IVI of anti-VEGF compared with
physician-administered IVI. Anti-VEGF IVI represents a
considerable workload on ophthalmologic clinics and
will probably continue to do so in the near future. Ex-
tending the roles of other health workers may relieve
this workload from ophthalmologists and several clinics
have had good experience training nurses to perform
IVIs independently [11–14]. However, none have as far
as we know, investigated the safety, cost and patient ac-
ceptance of independent IVI administration by trained
nurses in a RCT.
We have chosen visual acuity as the primary outcome
of the present study. The major goal is to investigate
safety of nurse-administered IVI and visual acuity is rec-
ommended by health authorities in clinical trials when
investigating this outcome [19]. Furthermore, most pa-
tients probably want to be sure that nurse-administered
IVI does not pose any increased risk of deteriorating
their sight.
It is conceivable that several aspects of the IVI proced-
ure may affect visual acuity: the injection technique may
be unsatisfactory performed so that the drug may not be
administered correctly into the tissue where it acts, con-
traindications may be misinterpreted putting the patient
at risk of complications or the treatment plan may be
misinterpreted so that patients receive IVI with too
lengthy intervals. The training and certification of the
nurses is a key in this context, and the present study is
in many ways a test of whether the training of nurses
was adequate or not.
We believe that the design of the study, the
randomization procedure and outcome measurements
will be of sufficient strength and quality to evaluate if
nurses are performing IVIs as safe as the standard care.
Both newly remitted patients and patients treated before
are invited to participate in the study and our experience
so far is that it is easier including patients familiar with
the treatment than the newly remitted patients. If few
newly diagnosed patients are included, the interpretation
of results will be for the follow-up patients only.
The present study is not dimensioned to evaluate
whether there is an increased risk of complications that
need treatment, since the rates of these complications
are very low. Given that nurse-administered IVI is safe,
we find the secondary outcomes equally relevant and of
great importance to examine adverse events, patient sat-
isfaction and economic aspects.
Trial status
The first patient was recruited to the trial March 1. 2015
and recruitment ended December 2015. Data collection
will continue until January 2017.
Additional files
Additional file 1: EQS assistant. Instructions for the assisting nurse,
preparing the patients for intravitreal injections. (PDF 202 kb)
Additional file 2: EQS operator. Instructions for the operator performing
the intravitreal injections. (PDF 188 kb)
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Additional file 3: Daily report. Recording the number of patients and
eyes treated and the number of questions asked a senior consultant.
(PDF 172 kb)
Additional file 4: Patient report. Recording the use of health care
service. (PDF 97 kb)
Additional file 5: Patient satisfaction questionnaire. A short
questionnaire about satisfaction with the treatment asked after the first
and last visit. (PDF 98 kb)
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